SOVREMENNAYA PEDIATRIYA.2016.1(73):33-39; doi10.15574/SP.2016.73.33 

New features of the use of multistrain synbiotic in pediatric practice 

Berezhnoi V. V., Kozachuk V. G.

P.L. Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine 

The article presents a contemporary view of the intestinal microbiocenosis and the role of probiotic strains in the correction of dysbiosis in the light of evidence-based clinical research. The expediency of the use of synbiotics Rotabiotik and Rotabiotik baby in the prevention and correction of dysbiosis in various pathological conditions and functional disorders of the gastrointestinal tract in children is shown. 

Keywords: synbiotics, probiotic strains, children, Rotabiotik. 

REFERENCES

1. Andreeva IV. 2011. Sovremennyie dokazatelnyie dannyie effektivnosti primeneniya Lactobacillus Rhamnosus GG i Bifidobacterium Lactis ВB-12 v pediatricheskoy praktike. Vopr sovr pediatrii. 10(1): 50—57.

2. Abaturov AE, Gerasimenko ON, Vyisochina IL i dr. 2013. Bakteritsidnaya aktivnost probioticheskih sredstv. Zdorove rebenka. 8(51): 95—97.

3. Berezhniy VV. 2013. PedIatrIya. NatsIonalniy pIdruchnik. Za red prof VV Berezhnogo. KiYiv. TI: 1037.

4. Voronenko YuV, Shekera OG, Berezhniy VV. 2015. AktualnI pitannya pedIatrIYi v praktitsI sImeynogo lIkarya. Navchalniy posIbnik dlya lIkarIv-InternIv I lIkarIv sluhachIv zakladIv (fakultetIv) pIslyadiplomnoYi osvIti. KiYiv, Vidavets Zaslavskiy OYu: 342.

5. Doll M. 2007. Probiotiki i ih znachenie dlya organizma. Biologicheskaya meditsina. 13; 1: 11—15.

6. Zaharov IN, Dmitrieva YuA 2013. Shtamm-spetsificheskie svoystva Bifidobacterium animalis subsp. lactis Bb-12. Pediatriya. 2.

7. Ivahnenko OS. 2013. EfektivnIst zastosuvannya probIotichnoYi terapIYi u dItey rannogo vIku z harchovoyu alergIEyu. Zdorove rebenka. 6(49): 48—52.

8. Shadrin OG, Misnik VP, Ponomareva IG, Klimenko LA. 2014. On the question of formation of bowel eubiosis during the artifical infant feefing. Sovremennaya pediatriya. 1(57): 122—127.

9. Agafonova EA, Petrenko LL, Leonenko NI i dr. 2010. Klinicheskoe i immunologicheskoe znachenie probioticheskoy terapii u detey. Zdorove rebenka. 2(23): 61—64.

10. Kornienko EA. 2007. Sovremennyie printsipyi vyibora probiotikov. Detskie infektsii. 3: 64—69.

11. Maev IV, Kucheryavyiy YuA, Andreev DN. 2014. Aktualnyie vozmozhnosti optimizatsii antihelikobakternoy terapii. Lechaschiy vrach. 4: 73—79.

12. Nikolaeva TN, Zorina VV, Votrin SV. 2007. Analiz vliyaniya probioticheskih shtammov laktobakteriy v podderzhanii immunnogo gomeostaza makroorganizma. Klinicheskoe pitanie. 1-2: 56.

13. Kornienko EA, Mazankova LN, Belyaeva IA i dr. 2015. Primenenie probiotikov v pediatrii: analiz lechebnogo i profilakticheskogo deystviya s pozitsiy dokazatelnoy meditsinyi. Lechaschiy vrach. 9: 52—61.

14. Pro zatverdzhennya protokolIv medichnoYi dopomogi dItyam Iz zahvoryuvannyami organIv travlennya. Nakaz MOZ Ukrayini 29.01.2013 № 59. http://www.moz.gov.ua.

15. Horoshilova NV. 2013. Immunomoduliruyuschee i lechebnoe deystvie bifido- i laktobakteriy u detey s allergicheskimi zabolevaniyami i chastyimi respiratornyimi infektsiyami. Vopr sovr pediatrii. 5: 86—89.

16. Shvets OV. 2012. Zastosuvannya probIotikIv u gastroenterologIchnIy praktitsI. SImeyna meditsina. 6: 37—42.

17. Yankovskiy DS. 2005. Mikrobnaya ekologiya cheloveka: sovremennyie vozmozhnosti ee podderzhanie i vosstanovleniya. Kiev, Ekspert LTD: 361.

18. Shornikova AV, Casas IA, Mykkanen N et al. 1997. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J. 16: 1103—1107.

19. Blyakher МS, Lopatina ТK, Zhukova VM. 2002. Vliyanie Probiotikov na Produktsiyu Interferonov i Limfokinov. Probioticheskie Mikroorganizmy — Sovremennoe Sostoyanie Voprosa i Perspektivy Ispol'zovaniya. The Effect of Probiotics on the Production of Interferons and Lymphokines. Probiotic Microorganisms: The Present State and Prospects of Use. Proceedings of the Conference. Materialy Konferentsii. Moscow: 29.

20. Gueimonde M, Laitinen K, Salminen S, Isolauri E. 2007. Breast-milk: a symbiotic providing bifidobacteria and bifidogenic substrates for infant gut development and maturation? Abstracts of 40th Annual meeting of the ESPGHAN. PN1—07: 73.

21. Aloisio I, Santini C, Biavati B et al. 2012. Characterization of Bifidobacterium spp. strains for the treatment of enteric disorders in newborns. Appl Microbiol Biotechnol. 96(6): 1561—76. http://dx.doi.org/10.1007/s00253-012-4138-5. Epub 2012 May 17.

22. Rossi F, Marzotto M, Cremonese S et al. 2013. Diversity of Streptococcus thermophilus in bacteriocin production; inhibitory spectrum and occurrence of thermophilin genes. Food Microbiol. 35(1): 27—33. http://dx.doi.org/10.1016/j.fm.2013.02.006

23. Whonwell PJ, Altringer L et. al. 2006. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with imitable dowel syndrome. Am J Gastroenterol. 101: 1581—1590.

24. Gronlund MM, Lehtonen OP, Eerola E, Kepo PJ. 1999. Fecal microflora in healthy infants born by different methods of delivery. Pediatr Gastroenterol Nutr. 28: 19—25.

25. Gill H, Prasad J. 2008. Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol. 606: 423—547.

26. Novak FR, Almeida JAG, Vieira GO, Borba LM. 2001. Human colostrum: a natural source of probiotics? J Pediatr. 77(4): 265—270.

27. Abedi D, Feizizadeh S, Akbari V, Jafarian-Dehkordi A. 2013. In vitro antibacterial and anti-adherence effects of Lactobacillus delbrueckii subsp bulgaricus on Escherichia coli. Res Pharm Sci. 8(4): 260—8.

28. Shimazaki Y, Shirota T, Uchida K et al. 2008. Intake of dairy product and periodontal diseases: The hisayama study. J Periodontol. 79: 131—137.

29. Jonkers D, Stockbrugger R. 2007. Review article: Probiotics in gastrointestinal and liver diseases. Pharmacol Ther. 26; Suppl 2: 133—48.

30. Kligler B. 2008. Cohrss Aliment Pharmacol Theren A. Probiotics. Am Fam Physician. 78: 1073—1078.

31. Timmerman HM, Koning CJM, Mulder L et al. 2004. Monostrein, multistrein and multispecies probiotics. Int J Food Microbiol. 96: 219—233.

32. Ohland CL, Macnaughton WK. 2010. Probiotic bacteria and ontestinal erithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 298; 6: G807—G819. doi: 10/1152/ajpgi-00243.2009.

33. Senok AC et al. 2005. Probiotics: facts and myths. Clin Micr And Inf. 11; 12: 958—966.

34. Dunne C, Murphy L, Flynn S et al. 1999. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek. 76: 279—292.

35. Proceedings of the International Scientific Conference on Probiotics and Prebiotics YPC2010. Kosice, Slovakia. 2010: 15.

36. Mkrtchyan H, Gibbons S, Heidelberger S et al. 2010. Purification, characterisation and identification of acidocin LCHV, an antimicrobial peptide produced by Lactobacillus acidophilus n.v. Er 317/402 strain Narine. Int J Antimicrob Agents. 35(3): 255—60; http://dx.doi.org/10.1016/j.ijantimicag.2009.11.017.

37. Renye JAJr., Somkuti GA. 2013. BlpC-regulated bacteriocin production in Streptococcus thermophiles. Biotechnol Lett. 35(3): 407—12. http://dx.doi.org/10.1007/s10529-012-1095-0.

38. Rerksuppaphol S, Rerksuppaphol L. 2012. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 54(5): 682—687. http://dx.doi.org/10.1111/j.1442-200X.2012.03647.x; PMid:22507276

39. Rolfe RD. 2000. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 130; Suppl 2: 396—402.

40. Rusch K, Peters U. 2002. Der Darm — zentrale des immunsystems. Biol Med. 4: 176—180.

41. Salminen MK et al. 2006. Clin Inf Dis. 42: 35—44.

42. Sanders ME, Huisin't Veld J. 1999. Bringing a probiotic-containing functional food to the market: microbiological, product, regulatory and labeling issues. Antonie Van Leeuwenhoek. 76: 293—315.

43. Kianifar H, Ahanchian H, Grover Z et al. 2014. Synbiotic in the management of infantile colic: a randomised controlled trial. Paediаtrics Child Health. 50(10): 801—5; http://dx.doi.org/10.1111/jpc.12640. Epub 2014 Jun 24.

44. Szajewska H, Horvath A, Piwowarczyk A. 2010. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 32(9): 1069—1079. http://dx.doi.org/10.1111/j.1365-2036.2010.04457.x; PMid:21039671

45. Wang ZH, Gao QY, Fang JY. 2013. Meta-Analysis of the Efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 47(1): 25—32. http://dx.doi.org/10.1097/MCG.0b013e318266f6cf; PMid:23090045

46. Zou J, Dong J, Yu X. 2009. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 14(5): 97—107. http://dx.doi.org/10.1111/j.1523-5378.2009.00716.x; PMid:19751434